Cargando…

Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma

BACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. METHODS: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clin...

Descripción completa

Detalles Bibliográficos
Autores principales: BAO, WEI, HAN, QIANGUANG, GUAN, XIAO, WANG, ZIJIE, GU, MIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208045/
https://www.ncbi.nlm.nih.gov/pubmed/37304236
http://dx.doi.org/10.32604/or.2023.028051
_version_ 1785046587608662016
author BAO, WEI
HAN, QIANGUANG
GUAN, XIAO
WANG, ZIJIE
GU, MIN
author_facet BAO, WEI
HAN, QIANGUANG
GUAN, XIAO
WANG, ZIJIE
GU, MIN
author_sort BAO, WEI
collection PubMed
description BACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. METHODS: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk profiles of patients with ccRCC. Patients in each cohort were separated into high- and low-risk groups based on their risk scores. The clinical importance of the signature was assessed through survival, immune microenvironment, drug sensitivity, and nomogram analyses using R software. RESULTS: SLC25A23, SLC25A42, SLC5A1, SLC3A1, SLC25A37, SLC5A6, SLCO5A1, and SCP2 comprised the signatures of the eight SLC-related genes. Patients with ccRCC were separated into high- and low-risk groups based on the risk value in the training and validation cohorts; the high-risk group had a significantly worse prognosis (p < 0.001). The risk score was an independent predictive indicator of ccRCC in the two cohorts according to univariate and multivariate Cox regression (p < 0.05). Analysis of the immune microenvironment showed that immune cell infiltration and immune checkpoint gene expression differed between the two groups (p < 0.05). Drug sensitivity analysis showed that compared to the low-risk group, the high-risk group was more sensitive to sunitinib, nilotinib, JNK-inhibitor-VIII, dasatinib, bosutinib, and bortezomib (p < 0.001). Survival analysis and receiver operating characteristic curves were validated using the E-MTAB-1980 cohort. CONCLUSIONS: SLC-related genes have predictive relevance in ccRCC and play roles in the immunological milieu. Our results provide insight into metabolic reprogramming in ccRCC and identify promising treatment targets for ccRCC.
format Online
Article
Text
id pubmed-10208045
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tech Science Press
record_format MEDLINE/PubMed
spelling pubmed-102080452023-06-10 Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma BAO, WEI HAN, QIANGUANG GUAN, XIAO WANG, ZIJIE GU, MIN Oncol Res Article BACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. METHODS: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk profiles of patients with ccRCC. Patients in each cohort were separated into high- and low-risk groups based on their risk scores. The clinical importance of the signature was assessed through survival, immune microenvironment, drug sensitivity, and nomogram analyses using R software. RESULTS: SLC25A23, SLC25A42, SLC5A1, SLC3A1, SLC25A37, SLC5A6, SLCO5A1, and SCP2 comprised the signatures of the eight SLC-related genes. Patients with ccRCC were separated into high- and low-risk groups based on the risk value in the training and validation cohorts; the high-risk group had a significantly worse prognosis (p < 0.001). The risk score was an independent predictive indicator of ccRCC in the two cohorts according to univariate and multivariate Cox regression (p < 0.05). Analysis of the immune microenvironment showed that immune cell infiltration and immune checkpoint gene expression differed between the two groups (p < 0.05). Drug sensitivity analysis showed that compared to the low-risk group, the high-risk group was more sensitive to sunitinib, nilotinib, JNK-inhibitor-VIII, dasatinib, bosutinib, and bortezomib (p < 0.001). Survival analysis and receiver operating characteristic curves were validated using the E-MTAB-1980 cohort. CONCLUSIONS: SLC-related genes have predictive relevance in ccRCC and play roles in the immunological milieu. Our results provide insight into metabolic reprogramming in ccRCC and identify promising treatment targets for ccRCC. Tech Science Press 2023-04-10 /pmc/articles/PMC10208045/ /pubmed/37304236 http://dx.doi.org/10.32604/or.2023.028051 Text en © 2023 BAO et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
BAO, WEI
HAN, QIANGUANG
GUAN, XIAO
WANG, ZIJIE
GU, MIN
Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
title Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
title_full Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
title_fullStr Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
title_full_unstemmed Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
title_short Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
title_sort solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208045/
https://www.ncbi.nlm.nih.gov/pubmed/37304236
http://dx.doi.org/10.32604/or.2023.028051
work_keys_str_mv AT baowei solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma
AT hanqianguang solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma
AT guanxiao solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma
AT wangzijie solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma
AT gumin solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma